Recombinant Mouse IL-2 (carrier-free)

Pricing & Availability
Regulatory Status
RUO
Other Names
Interleukin-2, T cell growth factor (TCGF), Eosinophil differentiation factor (EDF), Killer cell helper factor (KHF), Macrophage-activating factor for cytotoxicity I (MAF-C I), Thymocyte differentiation factor (TDF)
Ave. Rating
Submit a Review
Product Citations
publications
IL-2_Mouse_Recombinant_Protein_BA_032913
HT-2 cell proliferation induced by mouse IL-2.
  • IL-2_Mouse_Recombinant_Protein_BA_032913
    HT-2 cell proliferation induced by mouse IL-2.
  • Recombinant_Mouse_IL-2_CF_012022
    Recombinant mouse IL-2 induces the proliferation of mouse HT-2 cell line in a dose dependent manner. BioLegend’s protein was compared side-by-side to a competitor’s equivalent product.
Cat # Size Price Quantity Check Availability Save
575410 2 µg £45
Check Availability


Need larger quantities of this item?
Request Bulk Quote
575402 10 µg £65
Check Availability


Need larger quantities of this item?
Request Bulk Quote
575404 25 µg £145
Check Availability


Need larger quantities of this item?
Request Bulk Quote
575406 100 µg £321
Check Availability


Need larger quantities of this item?
Request Bulk Quote
575408 500 µg £1003
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IL-2 is a potent lymphoid cell growth factor which exerts its biological activity primarily on T cells. Additionally, IL-2 has been found to stimulate growth and differentiation of B cells, NK cells, LAK cells, monocytes, and oligodendocytes.

Product Details
Technical Data Sheet (pdf)

Product Details

Source
Mouse IL-2, amino acids Ala21-Gln169 (Accession # NM_008366) was expressed in E. coli.
Molecular Mass
The 150 amino acid N-terminal methionylated recombinant protein has a predicted molecular mass of 17,231 Da. The DTT-reduced protein and non-reduced protein migrates at approximately 18kDa by SDS-PAGE.
Purity
Purity is >98%, as determined by Coomassie stained SDS-PAGE.
Formulation
0.22 µm filtered protein solution is in 5 mM NaH2PO4, 5 mM citric acid, 350 mM NaCl, 1 mM TCEP, pH 4.0.
Endotoxin Level
Endotoxin level is <0.1 EU/µg (<0.01ng/µg) protein as determined by the LAL method.
Concentration
10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity
ED50 = 0.2 - 1.0 ng/ml, corresponding to a specific activity of 1.0 - 5.0 x106 units/mg, as determined by the dose dependent stimulation of CTLL2 cell proliferation.

The specific activity of recombinant mouse IL-2 is approximately 9.07 x 104 IU/µg when compared against the Non WHO Reference Material for Murine Interleukin-2 (NIBSC code: 93/566) as determined by the dose dependent stimulation of CTLL2 cell proliferation.

ED50 = 0.4 - 2.0 ng/ml, corresponding to a specific activity of 0.5 - 2.5 x106 units/mg, as determined by the dose dependent stimulation of HT-2 cell proliferation.

For more information on specific activity, please visit the Recombinant Protein Unit Conversions page.
Application

Bioassay

Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Additional Product Notes

Get a 50% discount on this product when purchased in our Activation Bundles. Restrictions apply. Learn more…

Application References

(PubMed link indicates BioLegend citation)
  1. Detanico T, et al. 2011.J. Immunol. 187:82. PubMed
  2. Malu DT, et al. 2011. J. Immunol. 186:6271. PubMed
  3. Alcaide P, et al. 2012. J. Immunol. 188:1421. PubMed
  4. Williams JW, et al. 2013. Am J Physiol Lung Cell Mol Physiol. 305:693. PubMed
Product Citations
  1. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  2. Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed
  3. Jou E, et al. 2022. Sci Immunol. 7:eabn0175. PubMed
  4. Balood M, et al. 2022. Nature. 611:405. PubMed
  5. Benakis C, et al. 2022. Elife. 11: . PubMed
  6. An HW, et al. 2022. Cell Rep. 41:111878. PubMed
  7. Chan L, et al. 2022. Cells. 12: . PubMed
  8. Liu Z, et al. 2023. Breast Cancer Res. 25:10. PubMed
  9. Yang J, et al. 2021. Cancer Immunol Res. 9:200. PubMed
  10. Han S, et al. 2022. Cancer Immunol Res. 10:437. PubMed
  11. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  12. Kania AK, et al. 2022. J Immunol. 208:1873. PubMed
  13. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  14. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
  15. Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed
  16. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  17. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
  18. Adu-Berchie K, et al. 2023. Nat Commun. 14:3546. PubMed
  19. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  20. Ruscetti M, et al. 2020. Cell. 181:424. PubMed
  21. Liu B, et al. 2019. Nat Commun. 10:354. PubMed
  22. Zhou Z, et al. 2021. Nat Biomed Eng. 5:1320. PubMed
  23. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
  24. Sultan H, et al. 2018. Cancer Immunol Res. 6:617. PubMed
  25. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  26. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  27. Gomez–Lopez N, et al. 2019. J Immunol. 203:1793. PubMed
  28. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  29. Jacobsen JT, et al. 2021. Science. 373:. PubMed
  30. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
  31. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  32. Hrdinka M, et al. 2016. PLoS One. 11: 0162863. PubMed
  33. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  34. Takushi SE, et al. 2020. Hum Gene Ther. 31:626. PubMed
  35. Morales-Mantilla DE, et al. 2022. Elife. 11:. PubMed
  36. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
  37. Kania AK, et al. 2021. Immunohorizons. 5:918. PubMed
  38. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  39. Jacque E, et al. 2015. J Exp Med. 212:883. PubMed
  40. Swan G, et al. 2021. Front Immunol. 12:641188. PubMed
  41. Hills LB, et al. 2021. J Immunol. 206:89. PubMed
  42. Han S, et al. 2020. Oncoimmunology. 9:1737368. PubMed
  43. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  44. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  45. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  46. Pasciuto E, et al. 2020. Cell. 182:625. PubMed
  47. Zeis P, et al. 2020. Immunity. 53:775. PubMed
  48. Loo CS, et al. 2020. Immunity. 53:143. PubMed
  49. Minns D, et al. 2021. Nat Commun. 12:1285. PubMed
  50. Xu H, et al. 2021. J Clin Invest. 131:. PubMed
  51. Jiang P, et al. 2018. Nat Med. 24:1550. PubMed
  52. Mohammadpour H, et al. 2020. JCI Insight. 5:00. PubMed
  53. Roberts KJ, et al. 2021. Sci Rep. 11:19422. PubMed
  54. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  55. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  56. Knox T, et al. 2019. Sci Rep. 9:6136. PubMed
  57. Detanico T, et al. 2011. J Immunol. 187:82. PubMed
  58. Bao K, et al. 2016. J Immunol. 197(11):4371-4381. PubMed
  59. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
  60. Walker JA, et al. 2020. Immunity. 51(1):104-118. PubMed
  61. Frech M, et al. 2020. MethodsX. 7:101054. PubMed
  62. Choi HS, et al. 2020. Cell Rep. 30:2989. PubMed
  63. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed

Antigen Details

Structure
Cytokine
Bioactivity
Proliferation of T lymphocytes, B cells, anti-inflammatory, hematopoiesis, tumor surveillance
Cell Sources
T cells
Cell Targets
T cells, B cells, NK cells, LAK cells, monocytes, macrophages, oligodendrocytes
Receptors
High affinity heterotrimer of IL-2Rα/β/γ, intermediate affinity homodimer IL-2Rα (CD25; p55; Tac) and heterodimer IL-2Rβ (CD122)/γ; γ-subunit (CD132) in common with IL-4R, IL-7R, IL-13R, IL-15R
Cell Type
Embryonic Stem Cells, Hematopoietic stem and progenitors
Biology Area
Cell Biology, Stem Cells
Molecular Family
Cytokines/Chemokines
Regulation
Upregulated by NFAT; downregulated by TCF-8, CIF (colostrum inhibitory factor)
Gene ID
16183 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
IL-2
Specificity Alt (DOES NOT SHOW ON TDS):
IL-2
App Abbreviation (DOES NOT SHOW ON TDS):
BA
UniProt
View information about IL-2 on UniProt.org

Related FAQs

Why choose BioLegend recombinant proteins?

     • Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
     • Greater than 95% Purity or higher, tested on every lot of product.
     • 100% Satisfaction Guarantee for quality performance, stability, and consistency.
     • Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
     • Bulk and customization available. Contact us.
     • Learn more about our Recombinant Proteins.

How does the activity of your recombinant proteins compare to competitors?

We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!

What is the specific activity or ED50 of my recombinant protein?

The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.

Have your recombinants been tested for stability?

Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.

Does specific activity of a recombinant protein vary between lots?

Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.

How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?

Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)

Go To Top Version: 5    Revision Date: 05/04/2020

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account